Business Combination - Identifiable Intangible Assets (Details) - LymphaTech $ in Thousands |
Feb. 17, 2026
USD ($)
|
|---|---|
| Asset Acquisition | |
| Estimated Fair Value | $ 4,110 |
| Developed technology | |
| Asset Acquisition | |
| Estimated Fair Value | $ 3,200 |
| Estimated Useful Life | 10 years |
| Customer relationships | |
| Asset Acquisition | |
| Estimated Fair Value | $ 540 |
| Estimated Useful Life | 5 years |
| Tradenames | |
| Asset Acquisition | |
| Estimated Fair Value | $ 370 |
| Estimated Useful Life | 10 years |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|